16 hasil untuk "Amresh Raina"
Menampilkan 1–16 · 0,19 detik · RSS
-
Artikel Jurnal
Risk assessment in pulmonary arterial hypertension
Regular patient assessment is essential for the management of chronic diseases, such as pulmonary arterial hypertension (PAH). Comprehensive patient assessment and risk stratification in PAH are important to guide treatment decisions and to monitor disease progression as well as patients' response…
-
Artikel Jurnal
Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
The combination of bosentan and sildenafil is commonly used to treat patients with pulmonary arterial hypertension (PAH); however, there is evidence of a significant drug interaction between these two medications. We sought to evaluate the safety and efficacy of transitioning patients with PAH from…
-
Artikel Jurnal
Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable…
-
Artikel Jurnal Teks lengkap
Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study
Purpose : The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs. Methods : Adult health plan…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Congruency between clinician‐assessed risk and calculated risk of 1‐year mortality in patients with pulmonary arterial hypertension: A retrospective chart review
Abstract The objective of this analysis was to compare clinician‐based and formally calculated risk assessments by REVEAL Lite 2 and COMPERA 2.0 and to characterize parenteral prostacyclin utilization within 90 days of baseline in high‐risk patients. A multisite, double‐blind, retrospective chart…
-
Artikel Jurnal
Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
A comprehensive description of the contemporary trends in pulmonary arterial hypertension (PAH) related hospitalizations, associated inpatient outcomes and predictors of worse outcomes were reported in our paper recently published in the International Journal of Cardiology [1]. Our observational…
-
Artikel Jurnal
Rapidly progressive pulmonary hypertension and right ventricular failure in a heart and kidney transplant recipient
Abstract A 54‐year‐old man status post heart and kidney transplant presented with dyspnea. Imaging was consistent with lymphangitic carcinomatosis (LC), in the setting of biopsy proven adenocarcinoma. He developed pulmonary hypertension (PH) and died of right ventricular failure (RVF) 3 weeks…
-
Artikel Jurnal
Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with…
-
Artikel Jurnal
Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
To assess the relationship of cytokines with functional and clinical outcomes in pulmonary arterial hypertension (PAH). Endothelial dysfunction and vascular inflammation are characteristic of PAH. We investigated whether markers of angiogenesis and inflammation associated with functional…
-
Artikel Jurnal Teks lengkap
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
BACKGROUND: Achievement of low-risk status is a treatment goal in pulmonary arterial hypertension (PAH). Risk assessment often is performed using multiparameter tools, such as the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator. Risk calculators that assess…
-
Artikel Jurnal
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat…
-
Artikel Jurnal
Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
The phase 4 COMPASS-3 study evaluated whether a singular endpoint produces clinically meaningful outcomes in patients with pulmonary arterial hypertension (PAH). The relationship between cardiac magnetic resonance imaging (cMRI)-derived parameters and right heart catheterization (RHC) measurements…
-
Artikel Jurnal
Outcomes of patients hospitalized for acute pulmonary embolism by obstructive sleep apnea status
Pulmonary embolism (PE) is a major cause of cardiovascular morbidity and mortality. Obstructive sleep apnea (OSA) is increasingly recognized in the aging population, especially with the rising obesity epidemic. The impact of OSA on inpatient mortality in PE is not well understood. We used the…
-
Artikel Jurnal
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
Background Current mortality data for pulmonary arterial hypertension (PAH) in the United States are based on registries that enrolled patients prior to 2010. We sought to determine mortality in PAH in the modern era using the PHAR (Pulmonary Hypertension Association Registry). Methods and Results…